Clearside Biomedical Inc. (NASDAQ:CLSD) traded at a new 52-week high today of $5.04. So far today approximately 12 million shares have been exchanged, as compared to an average 30-day volume of 166,000 shares.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.
Based on a current price of $5.03, Clearside Biomedical Inc. is currently 45.9% above its average consensus analyst price target of $2.72.
In the past 52 weeks, shares of Clearside Biomedical Inc. have traded between a low of $1.25 and a high of $5.04 and is now at $5.03, which is 302% above that low price.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer